Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Alzheimer's Blockbuster Might Spur Investor Bonanza, Higher Medicare Costs
01:06pm, Wednesday, 28'th Sep 2022
Biogen's Alzheimer's drug results are breathing new life into a class of anti-amyloid drugs that had been partially written off.
Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study
12:47pm, Wednesday, 28'th Sep 2022
Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to p
Biogen stock shot up 40% on Wednesday: find out why
12:27pm, Wednesday, 28'th Sep 2022
Shares of Biogen Inc (NASDAQ: BIIB) shot up 40% on Wednesday after the biotech firm said its experimental Alzheimer's drug showed promising results in a Phase III trial.
Why Biogen, Lilly, and Prothena Stocks Are Skyrocketing Today
12:01pm, Wednesday, 28'th Sep 2022
Positive results for Biogen's Alzheimer's disease candidate are boosting all three stocks.
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
11:17am, Wednesday, 28'th Sep 2022 Benzinga
Gainers
Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.
Silo Pharma, Inc. (NASDAQ: SILO) rose 105% to $10.46 in pre-market tr
Nasdaq Futures Slip But S&P 500, Dow Futures Hold Up Ahead Of Market Open — Apple, Biogen Stocks In Focus
11:11am, Wednesday, 28'th Sep 2022 Benzinga
U.S. stocks could struggle for direction on Wednesday after the market struggled en route to a mixed close in the previous session. Volatility could be the order of the day as another batch of Fed sp
4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes
10:56am, Wednesday, 28'th Sep 2022
Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informatio
Why Is Biogen (BIIB) Stock Up 40% Today?
10:42am, Wednesday, 28'th Sep 2022
Today, we have a win-win for everyone except the short sellers. Biogen (NASDAQ: BIIB ) and Japanese pharmaceutical firm Eisai (OTCMKTS: ESALY ) are co-developing an experimental Alzheimer's disease dr
Medicare coverage of Eisai and Biogen's promising new Alzheimer's therapy is ‘another bridge to cross'
10:41am, Wednesday, 28'th Sep 2022
An experimental Alzheimer's disease treatment developed by Eisai and Biogen that appears to slow cognitive decline sent shares in both companies soaring, but some analysts are tempering their expectat
Biogen shares soar on Alzheimer's drug developments
10:25am, Wednesday, 28'th Sep 2022
A study found that Biogen's Alzheimer's drug lecanemab reduced cognitive and functional decline by 27% compared to a placebo over an 18-month period.
Biogen soars 43% after its Alzheimer's drug helps slow down cognitive decline in late-stage study
10:12am, Wednesday, 28'th Sep 2022
JPMorgan estimates the Alzheimer's drug could generate between $6 billion and $10 billion in peak sales.
Biogen Stock Jumps 35% After Promising Results For New Alzheimer's Drug
10:05am, Wednesday, 28'th Sep 2022
The company said Tuesday its new Alzheimer's treatment reduced cognitive decline by 27% compared to a placebo group in a late-stage clinical trial.
Biogen Explodes Higher After Alzheimer's Drug Succeeds In Final-Phase Test
09:23am, Wednesday, 28'th Sep 2022
Biogen stock exploded higher Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a final-phase test. The post Biogen Explodes Higher Afte
A Biotech Breakthrough Means Big Gains for These 2 Stocks
09:16am, Wednesday, 28'th Sep 2022
The news could be good for patients suffering from a debilitating disease.
Biogen Stock Surges More Than 50% in Premarket Trading
09:16am, Wednesday, 28'th Sep 2022
The shares of Biogen Inc (NASDAQ:BIIB) are seeing an unprecedented surge ahead of the open, last seen up 53.2% at $302.91 after announcing that the experimental Alzheimer's drug it developed in conjun
